Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow

J. E. Talmadge, E. Reed, K. Ino, A. Kessinger, C. Kuszynski, D. Heimann, M. Varney, J. Jackson, J. M. Vose, P. J. Bierman

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

A majority of patients with intermediate or high-grade non-Hodgkin's lymphoma (NHL) who are treated with high-dose chemotherapy (HDT) and hematopoietic stem cell transplantation subsequently relapse. Until recently, transplantation was associated with high morbidity and mortality and the focus was on improving the safety of this procedure. However, the use of growth factors and other supportive measures has successfully reduced treatment mortality to less than 5%. Therefore, new strategies need to be developed to eliminate the growth of any occult tumor cells reinfused with the stem cell products and the tumor cells remaining in the patient. One approach is to improve the immune function of the patients by a more rapid immune reconstitution and augmentation of effector cell function. We report studies comparing immune recovery following HDT and autologous peripheral stem cell transplantation (PSCT) as compared to autologous bone marrow transplantation (ABMT). These studies examined patients with intermediate and high-grade non-Hodgkin's lymphoma (NHL) who were treated with HDT and PSCT (n = 56) or ABMT (n = 60). The PSCT patients had a significantly faster recovery of circulating monocytes (CD14+ cells), natural killer ((NK) CD56+) cells, T helper (CD4+) cells, TCRγ/δ cells, and naive T lymphocytes (CD45RA+). Following ABMT there was a significantly more rapid increase in the frequency of T suppressor/effector (CD8+) cells, B (CD19+) cells, CD34+ cells, polymorphonuclear leukocytes (PMN) and memory T lymphocytes (CD45RO+). The CD4:CD8 and CD45RA:CD45RO ratios were consistently higher in the PSCT group as compared to ABMT suggesting an improved ratio of T helper to T effector/suppressor cells and naive T cells. The differences in cellular phenotype translated into improved T cell function (PHA mitogenesis) and T cell help (pokeweed mitogenesis). In addition, there was an accelerated reconstitution of NK cell activity following PSCT as compared to ABMT. The more rapid reconstitution of NK and T cells in patients rescued with PSCT as compared to ABMT may contribute to an improved clinical outcome. Further, patients receiving a PSCT may be more responsive to adjuvant immunotherapy following transplantation.

Original languageEnglish (US)
Pages (from-to)161-172
Number of pages12
JournalBone marrow transplantation
Volume19
Issue number2
DOIs
StatePublished - Jan 2 1997

Fingerprint

Peripheral Blood Stem Cell Transplantation
Autologous Transplantation
Transplantation
Bone Marrow
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
T-Lymphocytes
Natural Killer T-Cells
Drug Therapy
Phytolacca americana
B-Lymphocyte Subsets
Neoplastic Stem Cells
Mortality
Peripheral Blood Stem Cells
Hematopoietic Stem Cell Transplantation
Helper-Inducer T-Lymphocytes
Natural Killer Cells
Immunotherapy
Monocytes
Intercellular Signaling Peptides and Proteins

Keywords

  • BMT
  • Immunity
  • NHL
  • NK cell F
  • PSCT
  • T cell

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. / Talmadge, J. E.; Reed, E.; Ino, K.; Kessinger, A.; Kuszynski, C.; Heimann, D.; Varney, M.; Jackson, J.; Vose, J. M.; Bierman, P. J.

In: Bone marrow transplantation, Vol. 19, No. 2, 02.01.1997, p. 161-172.

Research output: Contribution to journalArticle

@article{305fae6a2f6a47cdadc075d38c4f0c26,
title = "Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow",
abstract = "A majority of patients with intermediate or high-grade non-Hodgkin's lymphoma (NHL) who are treated with high-dose chemotherapy (HDT) and hematopoietic stem cell transplantation subsequently relapse. Until recently, transplantation was associated with high morbidity and mortality and the focus was on improving the safety of this procedure. However, the use of growth factors and other supportive measures has successfully reduced treatment mortality to less than 5{\%}. Therefore, new strategies need to be developed to eliminate the growth of any occult tumor cells reinfused with the stem cell products and the tumor cells remaining in the patient. One approach is to improve the immune function of the patients by a more rapid immune reconstitution and augmentation of effector cell function. We report studies comparing immune recovery following HDT and autologous peripheral stem cell transplantation (PSCT) as compared to autologous bone marrow transplantation (ABMT). These studies examined patients with intermediate and high-grade non-Hodgkin's lymphoma (NHL) who were treated with HDT and PSCT (n = 56) or ABMT (n = 60). The PSCT patients had a significantly faster recovery of circulating monocytes (CD14+ cells), natural killer ((NK) CD56+) cells, T helper (CD4+) cells, TCRγ/δ cells, and naive T lymphocytes (CD45RA+). Following ABMT there was a significantly more rapid increase in the frequency of T suppressor/effector (CD8+) cells, B (CD19+) cells, CD34+ cells, polymorphonuclear leukocytes (PMN) and memory T lymphocytes (CD45RO+). The CD4:CD8 and CD45RA:CD45RO ratios were consistently higher in the PSCT group as compared to ABMT suggesting an improved ratio of T helper to T effector/suppressor cells and naive T cells. The differences in cellular phenotype translated into improved T cell function (PHA mitogenesis) and T cell help (pokeweed mitogenesis). In addition, there was an accelerated reconstitution of NK cell activity following PSCT as compared to ABMT. The more rapid reconstitution of NK and T cells in patients rescued with PSCT as compared to ABMT may contribute to an improved clinical outcome. Further, patients receiving a PSCT may be more responsive to adjuvant immunotherapy following transplantation.",
keywords = "BMT, Immunity, NHL, NK cell F, PSCT, T cell",
author = "Talmadge, {J. E.} and E. Reed and K. Ino and A. Kessinger and C. Kuszynski and D. Heimann and M. Varney and J. Jackson and Vose, {J. M.} and Bierman, {P. J.}",
year = "1997",
month = "1",
day = "2",
doi = "10.1038/sj.bmt.1700626",
language = "English (US)",
volume = "19",
pages = "161--172",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow

AU - Talmadge, J. E.

AU - Reed, E.

AU - Ino, K.

AU - Kessinger, A.

AU - Kuszynski, C.

AU - Heimann, D.

AU - Varney, M.

AU - Jackson, J.

AU - Vose, J. M.

AU - Bierman, P. J.

PY - 1997/1/2

Y1 - 1997/1/2

N2 - A majority of patients with intermediate or high-grade non-Hodgkin's lymphoma (NHL) who are treated with high-dose chemotherapy (HDT) and hematopoietic stem cell transplantation subsequently relapse. Until recently, transplantation was associated with high morbidity and mortality and the focus was on improving the safety of this procedure. However, the use of growth factors and other supportive measures has successfully reduced treatment mortality to less than 5%. Therefore, new strategies need to be developed to eliminate the growth of any occult tumor cells reinfused with the stem cell products and the tumor cells remaining in the patient. One approach is to improve the immune function of the patients by a more rapid immune reconstitution and augmentation of effector cell function. We report studies comparing immune recovery following HDT and autologous peripheral stem cell transplantation (PSCT) as compared to autologous bone marrow transplantation (ABMT). These studies examined patients with intermediate and high-grade non-Hodgkin's lymphoma (NHL) who were treated with HDT and PSCT (n = 56) or ABMT (n = 60). The PSCT patients had a significantly faster recovery of circulating monocytes (CD14+ cells), natural killer ((NK) CD56+) cells, T helper (CD4+) cells, TCRγ/δ cells, and naive T lymphocytes (CD45RA+). Following ABMT there was a significantly more rapid increase in the frequency of T suppressor/effector (CD8+) cells, B (CD19+) cells, CD34+ cells, polymorphonuclear leukocytes (PMN) and memory T lymphocytes (CD45RO+). The CD4:CD8 and CD45RA:CD45RO ratios were consistently higher in the PSCT group as compared to ABMT suggesting an improved ratio of T helper to T effector/suppressor cells and naive T cells. The differences in cellular phenotype translated into improved T cell function (PHA mitogenesis) and T cell help (pokeweed mitogenesis). In addition, there was an accelerated reconstitution of NK cell activity following PSCT as compared to ABMT. The more rapid reconstitution of NK and T cells in patients rescued with PSCT as compared to ABMT may contribute to an improved clinical outcome. Further, patients receiving a PSCT may be more responsive to adjuvant immunotherapy following transplantation.

AB - A majority of patients with intermediate or high-grade non-Hodgkin's lymphoma (NHL) who are treated with high-dose chemotherapy (HDT) and hematopoietic stem cell transplantation subsequently relapse. Until recently, transplantation was associated with high morbidity and mortality and the focus was on improving the safety of this procedure. However, the use of growth factors and other supportive measures has successfully reduced treatment mortality to less than 5%. Therefore, new strategies need to be developed to eliminate the growth of any occult tumor cells reinfused with the stem cell products and the tumor cells remaining in the patient. One approach is to improve the immune function of the patients by a more rapid immune reconstitution and augmentation of effector cell function. We report studies comparing immune recovery following HDT and autologous peripheral stem cell transplantation (PSCT) as compared to autologous bone marrow transplantation (ABMT). These studies examined patients with intermediate and high-grade non-Hodgkin's lymphoma (NHL) who were treated with HDT and PSCT (n = 56) or ABMT (n = 60). The PSCT patients had a significantly faster recovery of circulating monocytes (CD14+ cells), natural killer ((NK) CD56+) cells, T helper (CD4+) cells, TCRγ/δ cells, and naive T lymphocytes (CD45RA+). Following ABMT there was a significantly more rapid increase in the frequency of T suppressor/effector (CD8+) cells, B (CD19+) cells, CD34+ cells, polymorphonuclear leukocytes (PMN) and memory T lymphocytes (CD45RO+). The CD4:CD8 and CD45RA:CD45RO ratios were consistently higher in the PSCT group as compared to ABMT suggesting an improved ratio of T helper to T effector/suppressor cells and naive T cells. The differences in cellular phenotype translated into improved T cell function (PHA mitogenesis) and T cell help (pokeweed mitogenesis). In addition, there was an accelerated reconstitution of NK cell activity following PSCT as compared to ABMT. The more rapid reconstitution of NK and T cells in patients rescued with PSCT as compared to ABMT may contribute to an improved clinical outcome. Further, patients receiving a PSCT may be more responsive to adjuvant immunotherapy following transplantation.

KW - BMT

KW - Immunity

KW - NHL

KW - NK cell F

KW - PSCT

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=17144456465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144456465&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700626

DO - 10.1038/sj.bmt.1700626

M3 - Article

C2 - 9116614

AN - SCOPUS:17144456465

VL - 19

SP - 161

EP - 172

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -